Epstein Secrets

n's international business, Richard Gnodde will give up $31 million in pay this year. In addition, the bank will take back millions in past pay from Solomon's predecessor, Lloyd Blankfein and other former executives. The Washington Post (10/22, Bogage, 14.2M) says, "Prosecutors in the Eastern District o

e AP (10/22, Marchione) reports that the "antiviral medicine given to hospitalized patients through an IV," being marketed by manufacturer Gilead as Veklury, "cut the time to recovery by five days - from 15 days to 10 on average - in a large study led by the U.S. National Institutes of Health." The drug

's international business, Richard Gnodde will give up $31 million in pay this year. In addition, the bank will take back millions in past pay from Solomon's predecessor, Lloyd Blankfein and other former executives. The Washington Post <https://vvww.washingtonpost.corn/business/2020/10/22/goldman-sachs-

63> (10/22, Marchione) reports that the "antiviral medicine given to hospitalized patients through an IV," being marketed by manufacturer Gilead as Veklury, "cut the time to recovery by five days - from 15 days to 10 on average — in a large study led by the U.S. National Institutes of Health." The drug

's international business, Richard Gnodde will give up $31 million in pay this year. In addition, the bank will take back millions in past pay from Solomon's predecessor, Lloyd Blankfein and other former executives. The Washington Post (10/22, Bogage, 14.2M) says, "Prosecutors in the Eastern District of

e AP (10/22, Marchione) reports that the "antiviral medicine given to hospitalized patients through an IV," being marketed by manufacturer Gilead as Veklury, "cut the time to recovery by five days - from 15 days to 10 on average - in a large study led by the U.S. National Institutes of Health." The drug